{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"183-558-328-073-57X","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"183-558-328-073-57X","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8759,"type":"PATENT","title":"University of Columbia","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":13487,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8203,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Searched applicants and Owners= \"Columbia Univ\", \"Univ Columbia\", \" Univ Colum*\", \"Colum* univ\", \"Univ* Colum* NOT British\".
Select more for logical Variants
Add to collection
Total patents: more than 10k
Searched applicants and Owners= \"Columbia Univ\", \"Univ Columbia\", \" Univ Colum*\", \"Colum* univ\", \"Univ* Colum* NOT British\".
Select more for logical Variants
Add to collection
Total patents: more than 10k
(a) obtaining a sample selected from a serum or plasma sample from the mammal, wherein the mammal is not experiencing an acute renal injury;
(b) determining the level of NGAL in the sample; and
(c) evaluating the chronic renal injury status of the mammal, based on the level of NGAL in the sample."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method according to Claim 1, wherein when the level of NGAL in the sample is less than a base cut-off level, the evaluated chronic renal injury status indicates normal kidney function, optionally wherein the base cut-off level is about 20 ng NGAL/mL of sample."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method according to Claim 1, wherein when the level of NGAL in the sample is at or above an intermediate cut-off level, and up to an upper cut-off level, the evaluated chronic renal injury status indicates a mild chronic renal injury, optionally wherein the intermediate cut-off level is about 45 ng NGAL/mL of sample, and the upper cut-off level is about 200 ng NGAL/mL of sample."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method according to Claim 1, wherein when the level of NGAL in the sample is at or greater than the upper cut-off level, the evaluated chronic renal injury status indicates advanced chronic renal injury, optionally wherein the upper cut-off level is about 200 ng NGAL/mL of sample."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, used for the detection any change in the chronic renal injury status of the mammal, wherein the sample of step (a) is a first sample, and further comprising the steps of:
(d) obtaining at least one subsequent sample selected from a serum or plasma sample after a period of time after obtaining the first sample;
(e) determining the level of NGAL in the at least one subsequent sample; and
(f) evaluating any change in the chronic renal injury status of the mammal, based on comparing the level of NGAL in the at least one subsequent sample to the level of NGAL in the first sample."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method according to Claim 5, wherein
(a) a higher level of NGAL in the subsequent sample as compared to the first sample is an indication of worsening of the chronic renal injury in the mammal, or
(b) a lower level of NGAL in the subsequent sample as compared to the first sample is an indication of improving of the chronic renal injury in the mammal."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of any of Claims 3 or 4, used for re-evaluating the chronic renal injury status after a treatment for chronic renal injury in the mammal, wherein the sample in step (a) is identified as a baseline sample, and further comprising the steps of:
(d) obtaining at least one post-treatment serum or plasma sample from the mammal after a treatment has been provided to the ammal for the chronic renal injury;
(e) determining the level of NGAL in the post-treatment sample; and
(f) re-evaluating the chronic renal injury status of the mammal after the treatment, based on comparing the level of NGAL in the at least one post-treatment sample to the level of NGAL in the baseline sample."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method according to Claim 7, wherein a lower level of NGAL in the posttreatment sample as compared to the baseline sample is an indication of improving of the chronic renal injury in the mammal."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method according to any one of Claims 1-8, wherein the chronic renal injury is selected from the group consisting of chronic infections, chronic inflammation, glomerulonephritides, vascular diseases, interstitial nephritis, drugs, toxins, trauma, renal stones, long standing hypertension, diabetes, congestive heart failure, nephropathy from sickle cell anemia and other blood dyscrasias, nephropathy related to hepatitis, HIV, parvovirus and BK virus, cystic kidney diseases, congenital malformations, obstruction, malignancy, kidney disease of indeterminate causes, lupus nephritis, membranous glomerulonephritis, membranoproliferative glomerulonephritis, focal glomerular sclerosis, minimal change disease, cryoglobulinemia, ANCA-positive vasculitis, ANCA-negative vasculitis, amyloidosis, multiple myeloma, light chain deposition disease, complications of kidney transplant, chronic rejection of a kidney transplant, chronic allograft nephropathy, and the chronic effects of immunosuppressives."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claims 3 or 4, used for identifying the extent of chronic renal injury in a mammal over time, wherein the sample of step (a) is a first sample, and wherein the first sample is taken at a first time, further comprising the steps of:
(d) obtaining at least one subsequent serum or plasma sample obtained at a time which is subsequent to the first time;
(e) determining the level of NGAL in the at least one subsequent sample; and
(f) determining the extent of the chronic renal injury in the mammal over time, based on comparing the level of NGAL in the at least one subsequent sample to the level of NGAL in the first sample."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["A method for evaluating chronic renal injury status in a mammal wherein the mammal is not experiencing acute renal injury, an acute infection or acute inflammation, comprising the steps of:
(a) determining the level of NGAL in a sample of serum or plasma obtained from the mammalian subject; and
(b) evaluating the chronic renal injury status of the mammal, based on the level of NGAL in the sample; wherein;"],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method according to Claim 1, wherein a level of NGAL in the sample less than a base cut-off level of up to about 40 ng NGAL/mL of sample, indicates normal kidney function, optionally wherein the base cut-off level is about 20 ng NGAL/mL of sample."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method according to Claims 11-12 wherein the intermediate cut-off level is about 45 ng NGAL/mL of sample, and the upper cut-off level is about 200 ng NGAL/mL of sample."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claims 11-13, wherein the sample of step (a) is a first sample, and further comprising the steps of:(i) a level of NGAL in the sample at or above an intermediate cut-off level of between about 35 ng NGAL/mL to about 60 ng NGAL/mL of sample, and up to an upper cut-off level of about 150 ng NGAL /mL of sample, indicates subclinical or stable chronic renal injury; and(ii) a level of NGAL in the sample at or greater than the upper cut-off level of between about 150 ng NGAL/mL to about 230 ng NGAL/mL of sample, indicates advanced or worsening chronic renal injury status, and/or a greater risk of progressing to chronic renal failure.
(c) determining the level of NGAL in at least one subsequent sample obtained from the mammalian subject after a period of time from obtaining the first sample; and
(d) evaluating any change in the chronic renal injury status of the mammal, based on comparing the level of NGAL in the at least one subsequent sample to the level of NGAL in the first sample."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method according to Claims 11-14, wherein a higher level of NGAL in the subsequent sample as compared to the first sample is an indication of worsening chronic renal injury in the mammal, and a lower level of NGAL in the subsequent sample as compared to the first sample is an indication of improving chronic renal injury status in the mammal."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of any of claims 13-15, used for re-evaluating the chronic renal injury status after a treatment for chronic renal injury in the mammal, wherein the serum or plasma sample in step (a) or the at least one subsequent serum or plasma sample in step (c) is identified as a baseline sample, and further comprising the steps of:
(e) determining the level of NGAL in a post-treatment serum or plasma sample obtained from the mammal after a treatment has been provided to the mammal for the chronic renal injury; and
(f) re-evaluating the chronic renal injury status of the mammal after the treatment, based on comparing the level of NGAL in the at least one post-treatment serum or plasma sample to the level of NGAL in the baseline sample."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method according to Claim 16, wherein a lower level of NGAL in the post-treatment sample as compared to the baseline sample is an indication of improving chronic renal injury status in the mammal."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method according to any one of Claims 11-17, wherein the chronic renal injury includes or is caused by one selected from the group consisting of chronic infections, chronic inflammation, glomerulonephritides, vascular diseases, interstitial nephritis, drugs, toxins, trauma, renal stones, long standing hypertension, diabetes, congestive heart failure, nephropathy from sickle cell anemia and other blood dyscrasias, nephropathy related to hepatitis, HIV, parvovirus and BK virus, cystic kidney diseases, congenital malformations, obstruction, malignancy, kidney disease of indeterminate causes, lupus nephritis, membranous glomerulonephritis, membranoproliferative glomerulonephritis, focal glomerular sclerosis, minimal change disease, cryoglobulinemia, ANCA-positive vasculitis, ANCA-negative vasculitis, amyloidosis, multiple myeloma, light chain deposition disease, complications of kidney transplant, chronic rejection of a kidney transplant, chronic allograft nephropathy, and the chronic effects of imunosuppressives."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of any one of the preceding claims, wherein the mammal is a human."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method according to Claim 14, wherein period of time is at least a few weeks, or at least a month, or at least a few months, or at least semi-annual, or at least annual, or at any interval in between."],"number":20,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}